These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

878 related articles for article (PubMed ID: 9452329)

  • 21. GFAP and NfL as fluid biomarkers for clinical disease severity and disease progression in multiple system atrophy (MSA).
    Katzdobler S; Nübling G; Klietz M; Fietzek UM; Palleis C; Bernhardt AM; Wegner F; Huber M; Rogozinski S; Schneider LS; Spruth EJ; Beyle A; Vogt IR; Brandt M; Hansen N; Glanz W; Brockmann K; Spottke A; Hoffmann DC; Peters O; Priller J; Wiltfang J; Düzel E; Schneider A; Falkenburger B; Klockgether T; Gasser T; Nuscher B; Haass C; Höglinger G; Levin J
    J Neurol; 2024 Oct; 271(10):6991-6999. PubMed ID: 39254698
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder.
    Hansson O; Janelidze S; Hall S; Magdalinou N; Lees AJ; Andreasson U; Norgren N; Linder J; Forsgren L; Constantinescu R; Zetterberg H; Blennow K;
    Neurology; 2017 Mar; 88(10):930-937. PubMed ID: 28179466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. What features improve the accuracy of the clinical diagnosis of progressive supranuclear palsy-parkinsonism (PSP-P)?
    Williams DR; Lees AJ
    Mov Disord; 2010 Feb; 25(3):357-62. PubMed ID: 20108379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential pattern of brain-specific CSF proteins tau and amyloid-β in Parkinsonian syndromes.
    Süssmuth SD; Uttner I; Landwehrmeyer B; Pinkhardt EH; Brettschneider J; Petzold A; Kramer B; Schulz JB; Palm C; Otto M; Ludolph AC; Kassubek J; Tumani H
    Mov Disord; 2010 Jul; 25(9):1284-8. PubMed ID: 20589870
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement.
    Trysberg E; Nylen K; Rosengren LE; Tarkowski A
    Arthritis Rheum; 2003 Oct; 48(10):2881-7. PubMed ID: 14558094
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different metabolic patterns analysis of Parkinsonism on the 18F-FDG PET.
    Juh R; Kim J; Moon D; Choe B; Suh T
    Eur J Radiol; 2004 Sep; 51(3):223-33. PubMed ID: 15294329
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MR imaging index for differentiation of progressive supranuclear palsy from Parkinson disease and the Parkinson variant of multiple system atrophy.
    Quattrone A; Nicoletti G; Messina D; Fera F; Condino F; Pugliese P; Lanza P; Barone P; Morgante L; Zappia M; Aguglia U; Gallo O
    Radiology; 2008 Jan; 246(1):214-21. PubMed ID: 17991785
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes.
    Holmberg B; Johnels B; Ingvarsson P; Eriksson B; Rosengren L
    Parkinsonism Relat Disord; 2001 Sep; 8(1):23-31. PubMed ID: 11472877
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid NFL in the differential diagnosis of parkinsonian disorders: A meta-analysis.
    Ge F; Ding J; Liu Y; Lin H; Chang T
    Neurosci Lett; 2018 Oct; 685():35-41. PubMed ID: 30036569
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sleep disturbances and brain MRI morphometry in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy - a comparative study.
    Gama RL; Távora DG; Bomfim RC; Silva CE; de Bruin VM; de Bruin PF
    Parkinsonism Relat Disord; 2010 May; 16(4):275-9. PubMed ID: 20185356
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tau forms in CSF as a reliable biomarker for progressive supranuclear palsy.
    Borroni B; Malinverno M; Gardoni F; Alberici A; Parnetti L; Premi E; Bonuccelli U; Grassi M; Perani D; Calabresi P; Di Luca M; Padovani A
    Neurology; 2008 Nov; 71(22):1796-803. PubMed ID: 18971445
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cerebrospinal fluid Abeta42 levels in multiple system atrophy.
    Verbeek MM; Abdo WF; De Jong D; Horstink MW; Kremer BP; Bloem BR
    Mov Disord; 2004 Feb; 19(2):238-40; author reply 240-1. PubMed ID: 14978688
    [No Abstract]   [Full Text] [Related]  

  • 33. [A follow-up study on brainstem atrophy in progressive supranuclear palsy--when does brain MRI contribute to the differential diagnosis between progressive supranuclear palsy and Parkinson disease?].
    Yamamoto T; Oya Y; Ogawa M; Ogata K; Kawai M
    Rinsho Shinkeigaku; 2003 Jul; 43(7):392-7. PubMed ID: 14582364
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patterns of brain atrophy in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.
    Messina D; Cerasa A; Condino F; Arabia G; Novellino F; Nicoletti G; Salsone M; Morelli M; Lanza PL; Quattrone A
    Parkinsonism Relat Disord; 2011 Mar; 17(3):172-6. PubMed ID: 21236720
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CSF orexin levels of Parkinson's disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration.
    Yasui K; Inoue Y; Kanbayashi T; Nomura T; Kusumi M; Nakashima K
    J Neurol Sci; 2006 Dec; 250(1-2):120-3. PubMed ID: 17005202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CSF neurofilament proteins levels are elevated in sporadic Creutzfeldt-Jakob disease.
    van Eijk JJ; van Everbroeck B; Abdo WF; Kremer BP; Verbeek MM
    J Alzheimers Dis; 2010; 21(2):569-76. PubMed ID: 20555148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
    Magdalinou NK; Paterson RW; Schott JM; Fox NC; Mummery C; Blennow K; Bhatia K; Morris HR; Giunti P; Warner TT; de Silva R; Lees AJ; Zetterberg H
    J Neurol Neurosurg Psychiatry; 2015 Nov; 86(11):1240-7. PubMed ID: 25589779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy.
    Ashour R; Jankovic J
    Mov Disord; 2006 Nov; 21(11):1856-63. PubMed ID: 16941460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Glial fibrillary acidic protein and neurofilament in children with cerebral white matter abnormalities.
    Kristjánsdóttir R; Uvebrant P; Rosengren L
    Neuropediatrics; 2001 Dec; 32(6):307-12. PubMed ID: 11870586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B; Locascio JJ; Schulz-Schaeffer W; Sixel-Döring F; Trenkwalder C; Schlossmacher MG
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 44.